anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The recovery of hand and arm function is of critical importance for decreasing long-term care costs and increasing quality of life for individuals with tetraplegia due to spinal cord injury (SCI). A subset of these individuals, with injuries in the mid to low cervical spinal cord, are candidates for nerve transfer surgery. Nerve transfer surgery restores function after SCI through coaptation of redundant, intact donor nerves to recipient nerves arising at or below the level of SCI. The use of nerve transfer after SCI is relatively novel and many patients exhibit a remarkable recovery of hand and arm motor function in the months that follow, however others show a much more limited recovery. The extent of recovery is likely limited, in part, by variability in rehabilitation and the ability of the motor cortex to incorporate the new peripheral circuitry resulting from this surgical procedure. There is a critical need to determine the response of cortical motor networks to nerve transfer and the role that rehabilitation plays in supporting cortical plasticity and motor recovery. If this need is not met, incomplete recovery from this state-of-the-art surgical intervention will persist and the potential application to a wider patient population will not be realized.

The investigators will test the central hypothesis that nerve transfer surgery after cervical SCI creates a novel cortical motor network, which can support the return of dexterous hand/forelimb function through rehabilitation-dependent remodeling. The hypothesis has been based upon 1) previous work in an animal model showing that rehabilitation reshapes cortical motor maps, 2) the pioneering work of a handful of clinicians, including the study collaborator, Justin Brown, that have applied nerve transfer to bypass spinal levels affected by injury, and 3) recent work using transcranial magnetic stimulation (TMS) in human SCI to map the cortical representation of arm muscles in the zone of partial preservation, and the ability to improve hand-arm function through intensive robotic training in chronically impaired subjects. The use of TMS to map cortical motor networks will allow the investigators to measure the cortical reorganization resulting from nerve transfer and determine the extent to which rehabilitation can engage this alternative cortical motor network. The rationale for the proposed studies is that a determination of the mechanisms that support rehabilitation-mediated recovery after nerve transfer will be required for optimizing and refining current clinical practice.
The invention provides a method and system for developing and using diagnoses of one or more underlying health affections in humans or an animal specie using a plurality of biomarkers. A target one or more affections are defined and a set of biomarkers is selected. An index is computed based on the measured levels of the biomarkers. The biomarkers levels are discretized, and each discrete value is multiplied by a corresponding coefficient. The index scale is divided into ranges that are matched with health statuses. A subject's health affection status is subsequently determined by measuring the level of each biomarker in the set, computing the index and matching the index value to the predefined index scale.
Patients receive melphalan IV over 30 minutes on days -5, fludarabine phosphate IV over 1 hour on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously for approximately 2 weeks, then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 100, and filgrastim SC daily from day 7 until continued until ANC \> 1,500/mm\^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
Dietary Therapy has been shown to be successful in the treatment of adult and pediatric patients with eosinophilic esophagitis Dietary studies were initially reported in children, but the results appear to be similar in adult patients. Elemental diets are successful in 70-95% of patients but are poorly tolerated. A six food elimination diet has been effective in about 70% of adult patients with EoE . In these adult studies skin prick testing was not helpful in predicting which foods would lead to a flare of disease when reintroduced into the diet. Therefore, the current standard of care requires multiple EGDs with esophageal biopsy during the dietary restriction and reintroduction phases of this study. Since the investigators are making lifelong dietary decisions during this process of food reintroduction, it is imperative the investigators be accurate. Unfortunately, these multiple EGDs have significant cost and are invasive procedures with some risk. Moreover, there is significant indirect costs with travel and time off work for the patients and drivers. Previous studies have found the esophageal sponge to be an accurate technique of accessing esophageal eosinophilia in EoE . The sponge is swallowed as a 12 mm capsule on a string. The capsule rapidly dissolves upon entering the stomach and the sponge then expands and can be pulled out the mouth five minutes after ingestion. In previous studies, the procedure was very well tolerated and all patients preferred the sponge to endoscopy.

Therefore the sponge is a well tolerated, inexpensive, very low risk procedure that would be an ideal option to replace EGD esophageal sampling in the evaluation of dietary treatment of EoE.
PURPOSE: To prepare a cosmetic, containing an extract of Glycyrrhiza glabra Linne var. glandulifera Regel et Herder, an extract of Aloe ferox Miller, etc., and tocopherols, having high safety, excellent in beautifying and whitening effects and useful for preventing and treating dermal stains and ephelides. CONSTITUTION: This cosmetic is obtained by blending (A) an extract of Glycyrrhiza glabra Linne var. glandulifera Linne var. Regel et Herder with (B) an extract of Aloe ferox Miller, etc., and (C) tocopherols (preferably tocopherol acetate or natural vitamin E). The amounts of the blended ingredients are preferably 0.01-0.5wt.% ingredient (A), 0.05-2wt.% ingredient (B) and 0.05-0.2wt.% ingredient (C). The ingredient (A) is preferably obtained by thermally extracting a root of the Glycyrrhiza glabra Linne var. glandulifera Regel et Herder produced in China, etc., with an alcohol such as ethanol, then concentrating and drying the resultant extract.  The ingredient (B) is preferably prepared by freeze-drying an aqueous solution obtained by pressing a leaf of the Aloe ferox Miller, etc., then washing the resultant powder with ethanol, concentrating the wash liquid under a reduced pressure, subsequently dissolving the powder in purified water and crystallizing calcium oxalate and a resinous ingredient, further removing the formed crystal by filtration and then adding purified water to make as a 0.5% aqueous solution.
The present invention discloses an artificial biologic cannula and a production method thereof. Sodium alginate is used as main raw materials, and a water solution of hydrochloric acid and calcium chloride or a water solution of calcium chloride is used as coagulant. An alginate acid and sodium alginate hollow circular tube with desired size (tube diameter and wall thickness) and physical and mechanical properties is obtained by a hollow fiber spinning and drawing technology. The obtained alginate acid and sodium alginate hollow circular tube is chemically treated by a chitosan solution, and the alginate acid chitosan and calcium alginate artificial biologic cannula with good normal saline resistance property and appropriate absorption period is obtained. An appropriate quantity of nerve growth promoting factors can be added to the artificial biologic cannula, and the medicine release type artificial biologic cannula is obtained. The absorbable artificial biologic cannula has the advantages of good biocompatibility, no toxicity or inflammation reaction to organisms, easy degradation and absorption in vivo, appropriate degradation and absorption period, and artificial regulation and control. The artificial biologic cannula is capable of promoting the growth of Schwann cells and restraining the growth of fibroblasts.
The invention relates to bear bile cardio-reliever pill sustained release preparations, belongs to the development of new varieties of traditional Chinese medicine in the biological and new medical technology, and is the secondary development of famous traditional Chinese medicine and ethnic medicine. Nowadays, situation of cardiac-cerebral vascular disease (CCVD) preventing and treating is more and more serious, and in order to get rid of the threaten of CCVD outbreak before dawn, the most efficient method is to prepare medicine for treating the cardiovascular disease into sustained release preparations which can prolong medicine effects. Appropriate blood concentration can be provided for human body during a predetermined period based on needs, times of medicine taking are decreased, and good treatment effects can be obtained. The preparations are very convenient for sufferers, particularly patients taking medicine for a long time. According to the bear bile cardio-reliever pill sustained release preparations, ethocel is used as coating material to be prepared into membranes, and polyethylene glycol 6000 is added as porogen. When the sustained release coating containing the porogon contacts with water or digestive juice, the porogen part on the coating membranes is dissolved or falls off, the membranes form a micropore or spongy structure, and permeability of mediums and medicine is increased, accordingly, medicine release rate is adjusted.
PURPOSE:To produce the titled bleaching agent composed of the acidic creamy A pack containing H2O2 and the alkaline creamy B pack, giving a mixture having a specific consistency index and pH when the A pack is mixed with the equal amount of the B pack, and applicable easily without causing dripping. CONSTITUTION:The objective bleaching agent for useless hair is composed of the creamy A pack containing 2-4wt% H2O2 and having a pH of 3-4.5 and a consistency index of 380-500 and the creamy B pack having a pH of 8-10 and a consistency index of 380-500. Most of conventional two-pack type bleaching agent gives a pH value of about 10 after mixing the A pack with the B pack. Contrary to the above, the pH of the present bleaching agent is 7.8-9.8 after mixing to prevent damage of the skin. The consistency index is selected to 380- 500 which is the optimum range to impart excellent applicability to a cream. The present bleaching agent is creamy, applicable without dripping, and suitable solely for the bleaching of useless hair.
Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
The intervention group will receive a dose at day 1 of amantadine 100 mg followed by 100 mg amantadine after 6 hours. The following 4 consecutive days, study participants will receive a daily dose of 200mg amantadine, 100 mg (1 capsule) morning and 100 mg (1 capsule) evening, yielding 5 days of treatment in total (10 capsules in total).
First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
OBJECTIVES: Demand for rapid coagulation testing for massive transfusion events led to development of an emergency hemorrhage panel (EHP; hemoglobin, platelet count, prothrombin time/international normalized ratio, and fibrinogen), with laboratory turnaround time (TAT) of less than 20 minutes. Ten years on, we asked if current laboratory practices were meeting that TAT goal and differences were evident in TAT between the 2 major institutions in our system.
METHODS: We identified EHPs ordered at our 2 largest hospitals, February 2, 2021, to July 17, 2022, comparing order to specimen draw time, specimen draw to specimen received time, laboratory analytic time, and total TAT results from emergency department and operating room. Site 1 houses a level I trauma center; site 2 includes tertiary care, transplant, and obstetrics services.
RESULTS: In total, 1137 EHPs were recorded in our study period. Laboratory TAT was significantly faster at site 1 (~14 vs ~27 minutes, P < .01). Average laboratory TAT was under 20 minutes at site 1 but only for 50% of specimens at site 2. Outlier specimens were collection delays at site 1 and specimen processing delays at site 2.
CONCLUSIONS: The EHP can be performed as rapidly as described. However, compromises in laboratory location, available personnel, and processing differences can degrade performance.
Inform women of childbearing potential that ASTAGRAF XL can harm the fetus. Instruct male and female patients to discuss with their healthcare provider family planning options including appropriate contraception. Also, discuss with pregnant patients the risks and benefits of breastfeeding their infant [see Use in Specific Populations (8.1, 8.2, 8.3)].

Encourage female transplant patients who become pregnant and male patients who have fathered a pregnancy, exposed to immunosuppressants including tacrolimus, to enroll in the voluntary Transplantation Pregnancy Registry International. To enroll or register, patients can call the toll free number 1-877-955-6877 or https://www.transplantpregnancyregistry.org/ [see Use in Specific Populations (8.1)].

Based on animal studies, ASTAGRAF XL may affect fertility in males and females [see Nonclinical Toxicology (13.1)].
Cases of overdose of up to 10 times the recommended bolus or continuous infusion dose of Angiomax have been reported in clinical trials and in postmarketing reports. A number of the reported overdoses were due to failure to adjust the infusion dose of bivalirudin in persons with renal dysfunction including persons on hemodialysis [see Dosage and Administration (2.2)]. Bleeding, as well as deaths due to hemorrhage, have been observed in some reports of overdose. In cases of suspected overdosage, discontinue Angiomax immediately and monitor the patient closely for signs of bleeding. There is no known antidote to Angiomax. Angiomax is hemodialyzable [see Clinical Pharmacology (12.3)].
The diaphragm produces a craniocaudal movement of its dome during contraction, making it the most crucial breathing muscle due to its unique anatomical structure and contribution to minute ventilation (60%-80%). Patients with (COPD) or asthma often develop diaphragmatic dysfunction (DD). This DD is related to the mechanical linkage between its various parts, placing it at a mechanical disadvantage to the muscle fibers. The capacity of the diaphragm to elevate and extend the lower rib cage at the level of the zone of apposition is impaired by this pathological change. This change increases the work of breathing and weakens the diaphragm. People with moderate or severe asthma may experience pulmonary overstretching, which can lead to functional issues. How physiotherapy may increase the mechanical efficiency of the thoracic cage and the effectiveness of the respiratory muscles during breathing has been the main focus of studies in recent decades. Although the use of specific diaphragm MT techniques does not yet have sufficient research documentation, recently published studies reported that there are indications to support their positive effect on pulmonary rehabilitation. The efficacy of diaphragm MT methods has not been investigated in adults with asthma, although it has been investigated in pediatric asthma. The effect of diaphragms MT techniques in combination with BRE has not been investigated. The present study hypothesizes that the combination of the mentioned physiotherapy techniques will contribute positively to the length-tension relationship and mobility of the diaphragm and chest expansion in patients with asthma. Secondary positive improvements are expected in the domain of functionality, (b) the feeling of dyspnea, (c) disease control and (d) abnormal respiratory pattern. The amplification of the above in people with asthma using respiratory standards and applying diaphragm mobilization techniques will contribute to better disease management.
The invention relates to a purple fimbristipula beverage and a manufacturing method. The beverage mainly consists of purple fimbristipula fluid and compound syrup fluid. The purple fimbristipula fluid is made by extracting the dry leaves of the purple fimbristipula and water. The compound syrup fluid mainly consists of water and natural syrup. The invention has a light sour and sweet taste with no bitterness. The color is light purple. Compared with the present technique, the invention preserves the effective elements to the utmost extent, and the taste and the color of the soup have high stability, and the invention has the advantages of convenient drinking and carrying and so on. The invention has the function of quenching thirst, refreshing and so on, and has good health care effects of expelling toxin of the digestive system, removing blood fat, reducing the blood pressure of cardio-cerebrovascular system, and absorbing clots.
The purpose of the pilot study is to assess the effects of an 8-week program on improving mental health in depressed family caregivers of people with dementia. The program will involve 8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy (ACT) for 8 weeks. Also, the study aims to understand these caregivers' experiences in the program, including their perspectives on the app features and contents. We aim to recruit 8-10 people for this pilot project. Outcomes regarding caregivers' mental health and ACT processes will be collected at pretest and posttest (after the completion of the 8-week program) and compared over time (i.e., posttest scores compared to pretest). At posttest, acceptability and perceived usability of the app will be evaluated using the 10-item System Usability Scale and 30-40 minute individual interviews. Participants' characteristics will be summarized using descriptive statistics. Either the Wilcoxon signed-rank test (a non-parametric test) or the paired sample t-test (a parametric test) will be performed to test the exploratory hypothesis that participants' scores for the outcome measures would significantly improve at posttest compared to pretest. Because of the exploratory nature of the study, no adjustment of p values will be conducted for multiple statistical comparisons of the outcome measures. Statistical significance will be set at p \<.05, and the effect sizes derived from this pilot study will form a basis for determining a sample size with sufficient statistical power required for a subsequent clinical trial. Caregivers' experiences in the app use and perspectives on the developed app will be explored using individual Zoom interviews. Interpretative phenomenological analysis will be used to analyze the interview data.
Bendamustine plus subcutaneous Rituximab treatment of 6 cycles. Rituximab 1400mg subcutaneous over 5mins on day 1 and bendamustine 120mg/m2 + NS 500mL iv over 1hour on day 1 and 2.
Risk Summary: It is also not known whether succinylcholine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Animal reproduction studies have not been conducted with succinylcholine chloride. Succinylcholine should be given to a pregnant woman only if clearly needed. 

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinal Considerations: Plasma cholinesterase levels are decreased by approximately 24% during pregnancy and for several days postpartum. Therefore, a higher proportion of patients may be expected to show increased sensitivity (prolonged apnea) to succinylcholine when pregnant than when nonpregnant. 

Labor and Delivery: Succinylcholine is commonly used to provide muscle relaxation during delivery by caesarean section. While small amounts of succinylcholine are known to cross the placental barrier, under normal conditions the quantity of drug that enters fetal circulation after a single dose of 1 mg/kg to the mother should not endanger the fetus. However, since the amount of drug that crosses the placental barrier is dependent on the concentration gradient between the maternal and fetal circulations, residual neuromuscular blockade (apnea and flaccidity) may occur in the newborn after repeated high doses to, or in the presence of atypical plasma cholinesterase in, the mother.
Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
The invention discloses a medicament for treating facial paralysis. The medicament is prepared from the following raw materials in parts by weight: 50-150 parts of maple root, 50-150 parts of firmiana root, 50-150 parts of folium isatidis, 50-150 parts of ilex cornuta and 50-150 parts of rhus chinensis mill root. The medicinal materials are decocted into a decoction according to a conventional method. The preparation method comprises the following steps: mixing dried products of the raw medicinal materials in a weight ratio; adding water which is 3-5 times of the total amount of the raw medicinal materials; boiling with strong fire, and decocting with slow fire for 10-20 minutes; and filtering and removing dregs. The raw medicinal materials are sufficient and easily available in raw materials, low in cost and quick in response for treating paralysis, the effective rate of the medicament is 100 percent, the treatment is convenient, and a patient can accept treatment at home rather than in hospital, so that the trouble of the patient caused by going hospital back and forth or being in hospital due to the paralysis can be solved. The medicament has a wide development and application prospect.
Intense local inflammatory reactions including skin weeping or erosion can occur after few applications of Imiquimod Cream and may require an interruption of dosing [see Dosage and Administration (2) and Adverse Reactions (6)]. Imiquimod Cream has the potential to exacerbate inflammatory conditions of the skin, including chronic graft versus host disease.

Severe local inflammatory reactions of the female external genitalia can lead to severe vulvar swelling. Severe vulvar swelling can lead to urinary retention. Dosing should be interrupted or discontinued for severe vulvar swelling.

Administration of Imiquimod Cream is not recommended until the skin is completely healed from any previous drug or surgical treatment.
PURPOSE:To provide an agent for suppressing the increase in blood pressure, containing a pectinic acid salt as a main component, capable of suppressing the increase in the blood pressure without restraining the intake of salt and usable as a food additive without deteriorating the palatability of the food. CONSTITUTION:At least one kind of a pectinic acid salt selected from potassium salt, calcium salt and magnesium salt is added to a food in an amount of <=3pts., preferably 0.1-1pt. per 1pt. of the salt content of the food. In the case of a liquid seasoning, the use of beet pectin is preferable. The pectinic acid salt is produced from a refined pectin extracted from the leak, stalk, root or fruit of common higher plants. The blood pressure suppressing agent can be taken in the body in the form of a food such as jelly, jam, etc., or by adding to a processed food such as fish TSUKUDANI (a preserved food boiled down in soy), pickles, seasoning, etc. It may be taken after meals.